"Tule turvallisesti paikan päälle tai asioi etänä. Varaa aika verkkosivuiltamme tai asiakaspalvelun kautta numerosta 030 6000. Ajanvaraus on auki vuorokauden ympäri. Koko Suomen kattavaa toimipaikkaverkostoa täydentävät ympäri vuorokauden saatavilla olevat digitaaliset etäpalvelut. Lääkäri-chat päivystää ilman ajanvarausta 24/7. Voit myös varata ajan video- tai puhelinvastaanotolle valitsemallesi asiantuntijalle. Nopeasti hyvään hoitoon! Turussa oireiset infektiopotilaat hoidetaan Pulssin yksikössä. Käynti Humaliston Apteekin ja Pulssin välisestä sisäänkäynnistä (ei pääovesta)."

During the past decade, Terveystalo Pulssi conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 5 clinical trials were completed, i.e. on average, 38.5% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 3 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Terveystalo Pulssi" #1 sponsor was "Amgen" with 5 trials, followed by "H. Lundbeck A/S" with 3 trials sponsored, "Pfizer" with 3 trials sponsored, "Bayer" with 2 trials sponsored and "Biohit Oyj" with 2 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Terveystalo Pulssi" #1 collaborator was "Novartis" with 3 trials as a collaborator, "The Finnish Funding Agency for Technology and Innovation (TEKES)" with 2 trials as a collaborator, "FGK Clinical Research GmbH" with 1 trials as a collaborator, "Hatanpää Hospital, Tampere" with 1 trials as a collaborator and "Helsinki University Central Hospital" with 1 trials as a collaborator. Other collaborators include 5 different institutions and companies that were collaborators in the rest 15 trials.

According to Clinical.Site data, the most researched conditions in "Terveystalo Pulssi" are "Migraine" (4 trials), "Cardiovascular Disease" (2 trials), "Chronic Cluster Headache" (2 trials), "Allergic Rhinitis" (1 trials) and "Atrial Fibrillation" (1 trials). Many other conditions were trialed in "Terveystalo Pulssi" in a lesser frequency.

Most popular intervention types in "Terveystalo Pulssi" are "Drug" (16 trials), "Other" (4 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (12 trials), "Eptinezumab" (3 trials), "Acetium" (2 trials), "Erenumab Dose 1" (2 trials) and "Erenumab Dose 2" (2 trials). Other intervention names were less common.

The vast majority of trials in "Terveystalo Pulssi" are 19 trials for "All" genders.

Currently, there are NaN active trials in "Terveystalo Pulssi". undefined are not yet recruiting, 4 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in Terveystalo Pulssi, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Terveystalo Pulssi, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 3 trials that are defined as “Not Applicable".